PCMU
MRVI icon

Paragon Capital Management (Utah)’s Maravai LifeSciences MRVI Stock Holding History

Paragon Capital Management (Utah)’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,587
Closed -$178K – 74
2024
Q1 		$178K Sell
20,587
-237,640
-92% -$1.61M 0.13% 64
2023
Q4 		$1.69M Buy
258,227
+139,074
+117% +$898K 1.35% 19
2023
Q3 		$1.19M Buy
119,153
+26,612
+29% +$292K 1.02% 41
2023
Q2 		$1.15M Buy
+92,541
New +$1.25M 0.97% 43

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Paragon Capital Management (Utah)'s MRVI Position: Q2 2024 in Review

Paragon Capital Management (Utah) sold out of Maravai LifeSciences (MRVI) in Q2 2024, closing a stake of 20,587 shares — an estimated $178K sold.

Paragon Capital Management (Utah) first reported a position in MRVI in Q2 2023 and held it in 4 quarters. The position peaked at $1.69M in Q4 2023. 206 funds tracked by Wall St. Rank hold MRVI as of Q2 2024.

  • Paragon Capital Management (Utah) reported no remaining Maravai LifeSciences position as of Q2 2024 after selling out during the quarter.
  • Paragon Capital Management (Utah) sold 20,587 Maravai LifeSciences shares in Q2 2024, an estimated $178K.
  • Paragon Capital Management (Utah) first reported a position in Maravai LifeSciences in Q2 2023 and held it in 4 quarters.
  • Paragon Capital Management (Utah)'s Maravai LifeSciences position peaked at $1.69M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2024.

Based on Paragon Capital Management (Utah)'s 13F filing for Q2 2024, filed 26 Sep 2024.